The application seeks approval for KERENDIA to treat chronic kidney disease in adults without diabetes.
Live Poll
Do you trust pharmaceutical companies to prioritize treatment research for the most common chronic conditions?
October 8, 2026
Developers Advanced Needle-Free Diabetes Drug OptionsNew non-invasive delivery methods aim to improve treatment adherence for patients with needle phobia.
October 7, 2026
GLP-1 Use Tied to Lower Sepsis Death RiskAdults with type 2 diabetes on GLP-1 therapy may face lower mortality if hospitalized for sepsis.
October 7, 2026
GLP-1 Use Linked to Low Pancreatitis Risk in YouthA new study of thousands of young patients shows few experienced acute pancreatitis while taking GLP-1 agonists.
October 7, 2026
FDA Granted Breakthrough Status to Sepsis TherapyThe designation aims to speed up the review of a new device for adults experiencing life-threatening hyperinflammation.
October 7, 2026
New Menin Inhibitor Will Enter Diabetes Drug PipelineA company will discuss preclinical data for a new oral medication being developed to potentially restore insulin production.
October 7, 2026
Peptron, Eli Lilly Evaluated New Diabetes Drug PlatformThe companies have completed a feasibility test for a potential once-monthly diabetes treatment.
October 6, 2026
Rezdiffra Maintained Efficacy Across Genetic MASH Risk VariantsA study found that common genetic variants do not affect how well this MASH treatment works for patients.
October 6, 2026
Bausch + Lomb Planned New Dry AMD Drug DevelopmentThe company has received FDA feedback on its path to studying an oral treatment for dry age-related macular degeneration.
October 6, 2026
New Shipping Container Launched for GLP-1 MedicationsAs demand for GLP-1 therapies grows, new specialized packaging aims to improve the mail-order delivery process.
October 6, 2026
Early-Onset Type 2 Diabetes Linked to NeurodiversityYoung adults diagnosed with type 2 diabetes show higher rates of autism and ADHD, new data indicates.
